Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

Advances in understanding the underlying pathophysiology of β-thalassemia have enabled efforts toward the development of novel therapeutic modalities. These can be classified into three major categories based on their ability to target different features of the underlying disease pathophysiology: correction of the α/β globin chain imbalance, targeting ineffective erythropoiesis, and targeting iron dysregulation. This article provides an overview of these different emerging therapies that are currently in development for β-thalassemia. Copyright © 2022 Elsevier Inc. All rights reserved.


Rayan Bou-Fakhredin, Kevin H M Kuo, Ali T Taher. Emerging Therapies in β-Thalassemia. Hematology/oncology clinics of North America. 2023 Apr;37(2):449-462

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 36907614

View Full Text